Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OriC902 in GPC3-positive Advanced HCC
NCT06891742Phase 1Recruiting
- Sponsor
- Peking University
- Start
- Feb 2025
- Primary completion
- Dec 2027
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of OriC902 in hepatocellular carcinoma (HCC), sponsored by Peking University. Primary endpoints: Maximum Tolerated Dose or Biologically Effective Dose at 1 year, Recommended Phase 2 Dose at 1 year and 1 more. Started Feb 2025; status: recruiting.
02
Drugs
OriC902
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06891742.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06891742.